Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Cadrenal Therapeutics, Inc. ( (CVKD) ).
On August 5, 2025, Cadrenal Therapeutics announced plans to initiate a clinical trial for tecarfarin, their lead late-stage drug candidate, targeting patients with end-stage kidney disease (ESKD) transitioning to dialysis. This trial aims to address a critical treatment gap for ESKD patients, who are at high risk for thrombotic cardiovascular events, by providing a potentially safer and more effective anticoagulant option. The trial will include patients with and without atrial fibrillation, and enrollment is set to begin later this year.
The most recent analyst rating on (CVKD) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.
Spark’s Take on CVKD Stock
According to Spark, TipRanks’ AI Analyst, CVKD is a Underperform.
The overall score reflects significant financial challenges, including ongoing losses and no revenue generation, which weigh heavily on the company’s outlook. Technical indicators suggest limited momentum, while valuation metrics highlight difficulties in assessing the stock’s fair value. Despite a positive corporate development with the appointment of a new Chief Medical Officer, the fundamental financial weaknesses remain the dominant concern.
To see Spark’s full report on CVKD stock, click here.
More about Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing transformative therapeutics to address the limitations of current anticoagulation therapy. Their lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation.
Average Trading Volume: 27,264
Technical Sentiment Signal: Sell
Current Market Cap: $20.32M
Learn more about CVKD stock on TipRanks’ Stock Analysis page.